Thomas J. Appio was named Chief Executive Officer of Bausch & Lomb Corp, succeeding Brent Saunders, effective October 12, 2026. As of November 6, 2026, Bausch & Lomb Corp has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 6, 2026 to October 28, 2026, naming 2 appointments and 2 departures (Form 8-K, October 13, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Bausch & Lomb Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Nathalie Bernier · 8-K, 2026-10-28
- · In / out: Out · Person: Brent Saunders · Role: Chief Executive Officer · Effective: 2026-10-12 · 8-K, 2026-10-13
- · In / out: In · Person: Laurence Paul · Role: Lead Independent Director · 8-K/A, 2026-08-12
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-06
Bausch & Lomb Corp reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-06 to 2026-10-28. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Bausch & Lomb Corp files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-28 | Out | 8-K, 2026-10-28 | |||
| 2026-10-13 | Out | Chief Executive Officer | 2026-10-12 | 8-K, 2026-10-13 | |
| 2026-10-13 | In | Chief Executive Officer | 2026-10-12 | 8-K, 2026-10-13 | |
| 2026-08-12 | In | Lead Independent Director | 8-K/A, 2026-08-12 | ||
| 2026-08-06 | Reported | not named in the filing | 8-K, 2026-08-06 |
Selling to them or working with them? See who runs Bausch & Lomb Corp now and the warning signs.
Free to see. No signup.
Watch Bausch & Lomb Corp
Get an email when Bausch & Lomb Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bausch & Lomb Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Bausch & Lomb Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bausch & Lomb Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Bausch & Lomb Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Brent Saunders, departure reported, effective 2026-10-12 (filed 2026-10-13). No successor is named in these filings.
- Lead Independent Director: Laurence Paul, appointed (filed 2026-08-12).
New leaders reset buying decisions — get the Full Report on Bausch & Lomb Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Bausch & Lomb Corp, with the record behind each one.
Find candidates like Chief Executive Officer at Bausch & Lomb CorpEvery change, in the filing's words
Departing: Nathalie Bernier
On October 28, 2026, Nathalie Bernier notified Bausch + Lomb Corporation (the "Company") of her decision to resign from the Board of Directors of the Company (the "Board") and from the Science and Technology Committee of the Board, effective at the close of business.
- In connection with Ms. Bernier's resignation and entry into a general mutual release of certain claims, the Company has agreed to pay Ms. Bernier prorated cash compensation for her service and to accelerate the vesting, in full, of the outstanding and unvested restricted share unit awards received by Ms. Bernier as part of her 2026 annual grant.
- The Board does not currently intend to fill the board vacancy created by Ms. Bernier's resignation.
- Ms. Bernier's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Departing: Brent Saunders, Chief Executive Officer, effective 2026-10-12
On October 12, 2026, Bausch + Lomb Corporation (the "Company") announced that Brent Saunders, Chief Executive Officer of the Company and a member of the Company's board of directors (the "Board"), and the Board have mutually agreed that Mr. Saunders will depart from the Company, effective as of October 12, 2026 (the "Separation Date").
Appointed: Thomas J. Appio, Chief Executive Officer, effective 2026-10-12
Thomas J. Appio, who is currently Chairman of the Board, was appointed to serve as the interim Chief Executive Officer of the Company, effective as of October 12, 2026.
- In connection with his departure, Mr. Saunders will also cease serving on the Board, effective as of the Separation Date.
- Mr. Saunders' departure from the Company and the Board is not due to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company's operations, policies or practices.
- Mr. Appio also serves as the Chief Executive Officer of Bausch Health Companies Inc. ("BHC"), the Company's controlling shareholder.
- In connection with Mr. Saunders' departure, the Company entered into a separation agreement with Mr. Saunders dated as of October 11, 2026 (the "Separation Agreement"), pursuant to which Mr. Saunders will receive (i) a lump-sum cash payment of $75.5 million in the aggregate, payable in accordance with the Separation Agreement, and (ii) reimbursement of his attorneys' fees in connection with the negotiation of the Separation Agreement up to $50,000 (collectively, the "Separation Consideration").
- Mr. Saunders will be eligible for continued participation in the Company's group health plans for two years following the Separation Date in accordance with his existing employment agreement with the Company, dated as of February 14, 2023 (as amended, the "Employment Agreement").
Appointed: Laurence Paul, Lead Independent Director
As of August 10, 2026, the Board has also appointed Dr. Paul to serve as Lead Independent Director.
- This Amendment No. 1 to the Initial 8-K is being filed to report that as of August 10, 2026, Mr. Appio has succeeded Brent Saunders in his capacity as Chairman of the Board, with Mr. Saunders continuing to serve as a member of the Board.
- Additionally, on August 10, 2026, the Board appointed Mr. Chersi as a member of its Audit and Risk Committee and Talent and Compensation Committee, Dr. Paul as a member of its Nominating and Corporate Governance Committee and Science and Technology Committee, John A. Paulson as chair of its Nominating and Corporate Governance Committee, Eduardo Alfonso, M.D. as chair of its Science and Technology Committee and Ms. Trebbi as chair of its Talent and Compensation Committee, each appointment effective August 10, 2026.
Reported
On August 6, 2026, Bausch + Lomb Corporation (the "Company") announced the appointment of Thomas J. Appio, Robert Chersi, Laurence Paul, M.D. and Barbara Trebbi to its board of directors (the "Board"), effective August 5, 2026, to fill the vacancies created by the resignations of Steven H. Collis, Karen L. Ling, Thomas W. Ross, Sr. and Andrew C. von Eschenbach, M.D.
- The Board has determined that each of Mr. Chersi, Dr. Paul and Ms. Trebbi is independent in accordance with applicable New York Stock Exchange and Toronto Stock Exchange rules and applicable Canadian securities laws.
- At the time of this filing, the Board has not yet determined the committee(s), if any, to which Mr. Appio, Mr. Chersi, Dr. Paul and Ms. Trebbi will be appointed, nor has the Board determined who will serve as lead independent director.
- Mr. Chersi, Dr. Paul and Ms. Trebbi will receive compensation in accordance with the Company's Non-Employee Directors Compensation Policy (as in effect from time to time), as described in the Company's 2026 Annual Proxy Statement, and each of Mr. Appio, Mr. Chersi, Dr. Paul and Ms. Trebbi have entered into the Company's standard form of director indemnification agreement.
- The new appointments were made at the request of Bausch Health Companies Inc. ("BHC"), the Company's controlling shareholder.
- Mr. Appio is the Chief Executive Officer of BHC.
- The resignations of the Resigning Directors were not due to any disagreement or dispute with the Company.
Tools for this story
Each opens in a new tab, filled in for Bausch & Lomb Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.